hotspot -WSS

hotspot

author：explore 2025-09-02 17:40:12 - browse：115

A pharmacist hands a box of Wegovy — first opinion coverage from STAT — Bloomberg photo by George Frey

LONDON — Novo Nordisk said Wednesday that it had started to increase the availability of its blockbuster obesity drug Wegovy for new patients in the United States, after massive demand and a supply crunch had led it to limit doses last May.

The announcement that Novo was making more of its lower-dose starter product available as of this month came as the company reported its 2023 earnings, with sales up by 36% and operating profit up 44% at constant exchange rates, driven by enormous sales of Wegovy and Ozempic, the company’s sister drug for diabetes. The company also projected double-digit growth in sales and operating profit for 2024.

“I am pleased to state that we are now enabling more new U.S. patients to initiate treatment by more than doubling the amount of lower-dose strength Wegovy compared to previous months,” Novo CEO Lars Fruergaard Jørgensen said on a call with reporters.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Protect nursing home residents from future pandemics

explore

WSS

Biogen’s boardroom scandal saddles CEO with first crisis

Some medical students still think black patients feel less pain

Stroke rates rising, especially in working

Louisiana bill approved classifying abortion pills as controlled substances

J&J reports mixed data on next

Decentralized clinical trials need collaboration to achieve wider use

explore

hotspot

entertainment

Drug repurposing or repositioning? The language matters

Maui wildfire now ranks as the fifth

Apple is now the first public company to be valued at $3 trillion

Medical students need to learn the potent medicine of empathy

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Bubonic plague hit France in 1720. Officials dithered. Sound familiar?

New air purifier tech could be key to improving indoor air quality

Guardant Health colon cancer test endorsed by FDA advisory panel

After affirmative action ruling, medical educators look to 'holistic review'

Be careful with at

focus

Novo Nordisk touts Wegovy study, but still struggling with supply

Be careful with at

U.S. death rates show how politics are affecting public health

Hospitals are dialing back on venture capital investing

Ozempic cut risk of death in diabetes patients with chronic kidney disease

Bird flu makes raw milk dangerous to consume, mouse study finds

leisure time

knowledge

explore

leisure time